Celartics Biopharma's dendritic cell-based vaccine against COVID-19 infection found to efficiently produce viral antigen-specific T lymphocytes

2020-05-22   

Results from ongoing study suggest the major role of Celartics' Cov-DCVax in preventing viral infection of COVID-19 and in controlling progression of the virus-associated diseasesBeijing, May 22, 2020, Celartics Biopharma announced today the filing of a patent application covering a novel dendritic cell (DC)-based vaccine, Cov-DCVax, to fight viral infection of COVID-19. The results, led by Celartics research team, demonstrate that using the proprietary engineered DC technology by targeting nucleoprotein (NP) of COVID-19, NP-specific cytotoxic CD8+ T cells from naive T lymphocytes can be efficiently induced and massively expanded in culture. The antigen-loaded DCs and viral antigen-specific T cells have great potentials in preventing viral infection and in controlling progression of virus-associated diseases, respectively.

Dendritic cells are the most potent professional antigen-presenting cells that can engulf and process viral or tumor antigens. Once DCs are loaded with viral antigen and become activated, they acquire the ability to educate naïve T lymphocytes, promoting these T cells to differentiate into antigen-specific cytotoxic T cells that can fight virus. Primary blood DCs constitute 1% of immune cells in peripheral blood and are not able to grow in culture. Manufacturing clinical grade DC with the conventional DC method, therefore, needs quite large amount of blood and is very costly, limiting DC’s application as a preventive vaccine against viral infection. To overcome various technical hurdles associated with the conventional DC method, Celartics Biopharma has developed an innovative engineered DC technology, which enables primary blood DCs from a few milliliters of peripheral blood to grow in culture, generating large amounts of highly activated DCs suitable for multiple clinical applications. These engineered DCs exhibit vastly improved antigen-loading capability and efficient lymphoid tissue homing ability due to high expression of the chemokine receptor, CCR7. In addition, the manufacturing cost for generating engineered DCs is significantly reduced. “The engineered DCs are safe to use, as demonstrated in animal studies and pilot clinical trial in cancer immunotherapy”, said Yang Yu, CEO of Celartics Biopharma

Current vaccine strategies for COVID-19 include mRNA vaccine, DNA vaccine, adenovirus vector-based vaccine and inactivated virus vaccine, with the goal of generating neutralizing antibody that reacts to Spike, the viral surface protein of COVID-19. The neutralizing antibody blocks entry of virus to host cells through ACE2 receptor. Accumulating evidences have suggested that developing permanent immunity remains challenging, exclusively by targeting heavily glycosylated Spike protein or rapidly mutating viral surface proteins such as influenza HA. Differing from these vaccine strategies, the engineered DCs are designed to empower T cells to fight virus. DC-educated T cells recognize viral antigenic peptides complexed with HLA molecules on the surface of virus-harboring host cells and launch subsequent attack to eliminate virus. Furthermore, a given viral protein in host cells is processed into multiple antigenic peptides that are bound to distinct HLA molecules, this provides many targets for antigen-specific T cells to attack. Unlike Spike protein, the NP protein of COVID-19 is less likely to mutate and also share 91% amino acid sequence homology with the counterpart of SARS virus. “The Cov-DCVax is designed to develop long-lasting protective immunity in human to fight both COVID-19 and SARS viruses”, said Yang Yu.

In last February, Celartics Biopharma announced the development of Human Dendritic Cell and Data Repository (HDCR), in order to meet urgent demands in fighting deadly virus outbreak and cancer. HDCR prepares human blood dendritic cells from healthy individuals in GMP facility, coupled with data analysis covering immunophenotyping and HLA typing. These engineered DCs are stored in liquid nitrogen and are readily available when needed, in supporting cell-based vaccination or immunotherapy. HDCR also serves as the platform technology provider to research institutions and pharmaceutical industries. The ultimate goal of HDCR is to bring in a feasibility of dendritic cells as a new form of preventive vaccines for rapidly evolving viruses. The Cov-DCVax vaccine is intended for generating long-lasting protective immunity in high risk individuals, while the viral antigen-specific T cells provide immediate therapeutic protection in controlling the progression of COVID-19-associated disease. "The current research progress and patent application enhance the spectrum of possible collaborators and partners. We are delighted that our scientific team has made solid progress in developing such unique Cov-DCVax vaccine, which may potentially yield benefits useful to high risk population, considering current global impact and severity of COVID-19 pandemic", said Yang Yu, CEO of Celartics Biopharma.


About Celartics Biopharma, Inc. Celartics Biopharma is a biotechnology company, located at Dongsheng International Science Park, Beijing. The company focuses on developing innovative cell-based immunotherapies for human cancer and viral diseases. The Company seeks rapidly advancing these technologies through pre-clinical and Phase I and II clinical trials, centering on DC therapeutic vaccine and adoptive T cell transfer therapies for treating solid cancer and leukemia. The company also seeks potential collaborators and partners for joint development through the proprietary technology platforms.

Ph.D., Chief Technology Officer, Celartics Biopharma, Inc.

Company :Celartics Biopharma Inc., Ltd.  

Contact: Huan Zhang,

Phone:010-6295 5880

Email: lily@celartics.com

Web:http://www.celartics.com/


Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.

Newest

  • Fun Spades: Bridging Tradition and Innovation, A Journey Through Card Game Excellence

    Fun Spades rose as one of the leading forces in digital card gaming. With over millions of thousands of downloads, the app bridges tradition and innovation, offering diverse game modes, sleek interface, and social features. It celebrates the rich heritage of Spades while embracing modernity through updates and events. Looking ahead to 2024, the app's development team is gearing up for an exciting journey filled with innovative updates and features. As the realm of digital card gaming evolves, Fun Spades stands out as a captivating and intellectually stimulating choice for card game enthusiasts
  • 3X Upgrade! Meet with VOOPOO's New Super Pods ARGUS P2&G2

    VOOPOO, a leading innovator in the vaping industry, is delighted to introduce two new additions to its esteemed ARGUS Pod series - ARGUS P2 and ARGUS G2. The two new super pods come with a 3X upgrade, fully upgrading the user's vaping experience.
  • Powerful Tool in the Market - AXIS-VIP Account

    As time passes, we are quickly approaching the launch of the second phase of the Wealth Express program. Veenit Jindal, the CEO of the Asia-Pacific region at the U.S. Bancorp, after extensive market research and several rounds of negotiations, has finally selected AXIS as the brokerage firm for this collaboration. This decision will involve the public issuance of a certain number of VIP accounts. These accounts offer a range of powerful features, ensuring smooth sailing for the success of the Wealth Express program!
  • Wall Street's Indian Titan - Top Analyst Sanjay Patel

    Sanjay Patel was born in Surat.From an early age, Sanjay Patel demonstrated a strong interest in numbers and analysis. His father was an innovative teacher, and his mother was a social worker dedicated to improving the living conditions of the underprivileged.
  • Wall Street's Indian Titan - Top Analyst Sanjay Patel

    Sanjay Patel was born in Surat.From an early age, Sanjay Patel demonstrated a strong interest in numbers and analysis. His father was an innovative teacher, and his mother was a social worker dedicated to improving the living conditions of the underprivileged.
  • ISEKY Goddess Invitation NFT to be Listed on Xterio Platform, Offering Numerous Benefits

    As early as January 8th, ISEKY officially announced its entry into the Xterio platform and released a teaser video for its flagship product, ISEKY: Soul GPS. The video immediately captured the hearts of Web3 users. Within just one hour, a large number of participants flooded into ISEKY's Discord channel, and their enthusiasm even triggered Discord's protective measures, prompting ISEKY to temporarily halt new user registrations. Recently, ISEKY announced that the Goddess Invitation NFT will be listed on the Xterio platform on March 21st, once again attracting the attention of WEB3 users. Accor
  • A new giant on the global stage: ZIOPTO exchange reinvents digital trading

    ZIOPTO exchange, which has risen rapidly in the field of digital currency, recently announced its global expansion and diversification strategy. This strategy aims to further consolidate its position in the international market and promote global financial cooperation.
  • Trading innovation: ZIOPTO exchange user experience revolution

    ZIOPTO Exchange, an innovator in the field of cryptocurrency trading, recently launched a major upgrade to its user interface (UI), aiming to provide a more intuitive and easier-to-use trading experience. This upgrade marks ZIOPTO's in-depth understanding of customer needs and rapid response to market trends.
  • Powering Up Panel-Level Packaging! Capcon’s Die Bonder Wins Bulk Adoption by Internationally Leading IDM Giant

    Recently, Capcon’s large panel-level packaging die bonder,AvantGo L6 (Leo), has been adopted in bulk by an Internationally Leading IDM manufacturer and mass producer. It is believed that with the bulk application of AvantGo L6 by client, it will lead the panel-level packaging equipment towards maturity, laying a solid foundation for the development of the panel-level packaging industry and opening a new chapter of advanced packaging with low cost and high efficiency.
  • Wall Street's Indian Titan - Top Analyst Sanjay Patel

    Sanjay Patel was born in Surat.From an early age, Sanjay Patel demonstrated a strong interest in numbers and analysis. His father was an innovative teacher, and his mother was a social worker dedicated to improving the living conditions of the underprivileged.

Links

Back to top
©copyright 2009-2020 Greeting Daily      Contact Us   SiteMap